Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntingtons disease

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1159-1183

  Toledo Sherman, Leticia M ^c   Prime, Michael E ^a   Mrzljak, Ladislav ^c   Beconi, Maria G ^c   Beresford, Alan ^g   Brookfield, Frederick A ^a   Brown, Christopher J ^a   Cardaun, Isabell ^b   Courtney, Stephen M ^a   Dijkman, Ulrike ^e   Hamelin Flegg, Estelle ^a   Johnson, Peter D ^a   Kempf, Valerie ^f   Lyons, Kathy ^d   Matthews, Kimberly ^g   Mitchell, William L ^a   Oconnell, Catherine ^g   Pena, Paula ^a   Powell, Kendall ^f   Rassoulpour, Arash ^e   Reed, Laura ^a   Reindl, Wolfgang ^b   Selvaratnam, Suganathan ^a   Friley, Weslyn Ward ^f   Weddell, Derek A ^a   Went, Naomi E ^a   Wheelan, Patricia ^f   Winkler, Christin ^b   Winkler, Dirk ^b   Wityak, John ^c   Yarnold, Christopher J ^a   Yates, Dawn ^g   Munoz Sanjuan, Ignacio ^c   Dominguez, Celia ^c   more..

^a EVOTEC UK LTD   (United Kingdom)

^b EVOTEC AG   (Germany)

^c CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^d Kathryn A Lyons   (United States)

^e CHARLES RIVER LABORATORIES   (United States)

^f Tandem Labs   (United States)

^g CHARLES RIVER LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,4 DIFLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLORO 2 FLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLORO 4 CYCLOBUTOXYPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLORO 4 CYCLOPROPOXYPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLORO 4 FLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLORO 4 METHOXYPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLORO 4 METHYLPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 CHLOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 FLUORO 4 METHYLPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 FLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 METHYLPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3 PHENYLPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3,4 DICHLOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (3,4 DIFLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (4 CHLORO 2 FLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (4 CHLORO 3 FLUOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (4 CHLOROPHENYL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (7 CHLOROBENZOFURAN 5 YL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 (PYRIDIN 3 YL)PYRIMIDINE 4 CARBOXYLIC ACID; 6 PHENYLPYRIMIDINE 4 CARBOXYLIC ACID; 6 [2 (TRIFLUOROMETHYL)PHENYL]PYRIMIDINE 4 CARBOXYLIC ACID; 6 [3 (TRIFLUOROMETHYL)PHENYL]PYRIMIDINE 4 CARBOXYLIC ACID; 6 [3 CHLORO 4 (CYCLOPENTYLOXY)PHENYL]PYRIMIDINE 4 CARBOXYLIC ACID; 6 [3 CHLORO 4 (PROPAN 2 YLOXY)PHENYL]PYRIMIDINE 4 CARBOXYLIC ACID; 6 [3 CHLORO 4 (TRIFLUOROMETHYL)PHENYL]PYRIMIDINE 4 CARBOXYLIC ACID; 6 [4 FLUORO 3 (TRIFLUOROMETHYL)PHENYL]PYRIMIDINE 4 CARBOXYLIC ACID; KYNURENINE; OXYGENASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR; KYNURENINE 3 MONOOXYGENASE; PYRIMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ARYLATION; CARBON NUCLEAR MAGNETIC RESONANCE; CELL DEATH; CELL PROLIFERATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENTIATION; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; HYDROGEN BOND; IC50; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SINGLE DRUG DOSE; SUZUKI REACTION; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL LINE; CRICETULUS; DOSE RESPONSE; DRUG EFFECTS; HUNTINGTON DISEASE; METABOLISM; MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; CELL PROLIFERATION; CHO CELLS; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HUNTINGTON DISEASE; KYNURENINE; KYNURENINE 3-MONOOXYGENASE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIMIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922765434     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501350y     Document Type: Article

References (68)

1. Reiner, A.; Dragatsis, I.; Dietrich, P. Genetics and neuropathology of Huntingtons disease Int. Rev. Neurobiol. 2011, 98, 325-372
2. Delmaire, C.; Dumas, E. M.; Sharman, M. A.; van den Bogaard, S. J.; Valabregue, R.; Jauffret, C.; Justo, D.; Reilmann, R.; Stout, J. C.; Craufurd, D.; Tabrizi, S. J.; Roos, R. A.; Durr, A.; Lehéricy, S. The structural correlates of functional deficits in early Huntingtons Disease Hum. Brain Mapping 2013, 34 (9) 2141-2153
3. Poon, L. H.; Kang, G. A.; Lee, A. J. Role of tetrabenazine for Huntingtons disease-associated chorea Ann. Pharmacother. 2010, 44 (6) 1080-1089
4. Schwarcz, R.; Bruno, J. P.; Muchowski, J. P.; Wu, H.-Q. Kynurenines in the mammalian brain: When physiology meets pathology Nat. Rev. Neurosci. 2012, 13 (7) 465-477
5. Vécsei, L.; Szalárdy, L.; Fülöp, F.; Toldi, J. Kynurenines in the CNS: Recent advances and new questions Nat. Rev. Drug Discovery 2013, 12 (1) 64-82
6. Mandi, Y.; Vecsei, L. The kynurenine systems and immunoregulation J. Neural. Transm. 2012, 119 (2) 197-209
7. Belenky, P.; Bogan, K. L.; Brenner, C. NAD+ metabolism in health and disease Trends Biochem. Sci. 2006, 32 (1) 12-19
8. Chen, Y.; Guillemin, G. J. Kynurenine Pathway Metabolites in Humans: Disease and Healthy States Int. J. Tryptophan Res. 2009, 2, 1-19
9. Schwarcz, R.; Guidetti, P.; Sathyasaikumar, K. P.; Muchowski, P. J. Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntingtons disease Prog. Neurobiol. 2010, 90, 230-245
10. Guidetti, P.; Luthi-Carter, R. E.; Augood, S. J.; Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntingtons disease Neurobiol. Dis. 2004, 17, 455-461
11. Guidetti, P.; Bates, G. P.; Graham, R. K.; Hayden, M. R.; Leavitt, B. R.; MacDonald, M. E.; Slow, E. J.; Wheeler, V. C.; Woodman, B.; Schwarcz, R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice Neurobiol. Dis. 2006, 23 (1) 190-197
12. Forrest, C. M.; Mackay, G. M.; Stoy, N.; Spiden, S. L.; Taylor, R.; Stone, T. W.; Darlington, L. G. Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntingtons disease J. Neurochem. 2010, 112, 112-122
13. Thevandavakkam, M. A.; Schwarcz, R.; Muchowski, P. J.; Giorgini, F. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntingtons disease CNS Neurol. Disord.: Drug Targets 2010, 9, 791-800
14. Giorgini, F.; Guidetti, P.; Nguyen, Q.; Bennett, S. C.; Muchowski, P. J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease Nat. Genet. 2005, 37 (5) 526-531
15. Campesan, S.; Green, E. W.; Breda, C.; Sathyasaikumar, K. V.; Muchowski, P. J.; Schwarcz, R.; Kyriacou, C. P.; Giorgini, F. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntingtons disease Curr. Biol. 2011, 21 (11) 961-966
16. Pellicciari, R.; Amori, L.; Costantino, G.; Giordani, A.; Macchiarulo, A.; Mattoli, L.; Pevarello, P.; Speciale, C.; Varasi, M. Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase Adv. Exp. Med. Biol. 2003, 527, 621-628
17. Amori, L.; Guidetti, P.; Pellicciari, R.; Kajii, Y.; Schwarcz, R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo J. Neurochem. 2009, 109 (2) 316-325
18. Heyes, M. P.; Chen, C. Y.; Major, E. O.; Saito, K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types Biochem. J. 1997, 326 (2) 351-356
19. Guillemin, G. J.; Smith, D. G.; Smythe, G. A.; Armati, P. J.; Brew, B. J. Expression of the kynurenine pathway enzymes in human microglia and macrophages Adv. Exp. Med. Biol. 2003, 527, 105-112
20. Rzeski, W.; Kocki, T.; Dybel, A.; Wejksza, K.; Zdzisińska, B.; Kandefer-Szerszeń, M.; Turski, W. A.; Okuno, E.; Albrecht, J. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons J. Neurosci. Res. 2005, 80 (5) 677-682
21. Schwarcz, R.; Pellicciari, R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities J. Pharmacol. Exp. Ther. 2002, 303, 1-10
22. Guillemin, G. J.; Cullen, K. M.; Lim, C. K.; Smythe, G. A.; Garner, B.; Kapoor, V.; Takikawa, O.; Brew, B. J. Characterization of the kynurenine pathway in human neurons J. Neurosci. 2007, 27, 12884-12892
23. Schwarcz, R.; Bruno, J. P.; Muchowski, P. J.; Wu, H. Q. Kynurenines in the mammalian brain: When physiology meets pathology Nat. Rev. Neurosci. 2012, 13, 465-477
24. Fukui, S.; Schwarcz, R.; Rapoport, S. I.; Takada, Y.; Smith, Q. R. Blood-Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism J. Neurochem. 1991, 56 (6) 2007-2017
25. Zwilling, D.; Huang, S. Y.; Sathyasaikumar, K. V.; Notarangelo, F. M.; Guidetti, P.; Wu, H. Q.; Lee, J.; Truong, J.; Andrews-Zwilling, Y.; Hsieh, E. W.; Louie, J. Y.; Wu, T.; Scearce-Levie, K.; Patrick, C.; Adame, A.; Giorgini, F.; Moussaoui, S.; Laue, G.; Rassoulpour, A.; Flik, G.; Huang, Y.; Muchowski, J. M.; Masliah, E.; Schwarcz, R.; Muchowski, P. J. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration Cell. 2011, 145 (6) 863-874
26. Chiarugi, A.; Carpenedo, R.; Moroni, F. Kynurenine Disposition in Blood and Brain of Mice: Effects of Selective Inhibitors of Kynurenine Hydroxylase and of Kynureninase J. Neurochem. 1996, 67 (2) 692-698
27. Saito, K.; Markey, S. P.; Heyes, M. P. Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse Neuroscience 1992, 51, 25-39
28. Klein, C.; Patte-Mensah, C.; Taleb, O.; Bourguignon, J.-J.; Schmitt, M.; Bihel, F.; Maitre, M.; Mensah-Nyagan, A. G. The neuroprotector kynurenic acid increases neuronal cell survival through neprilysin induction Neuropharmacology 2013, 70, 254-260
29. Stone, T. W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection Trends Pharmacol. Sci. 2000, 21 (4) 149-154
30. Stone, T. W.; Darlington, L. G. Endogenous kynurenines as targets for drug discovery and development Nat. Rev. Drug. Discovery 2002, 1 (8) 609-620
31. Storey, E.; Cipolloni, P. B.; Ferrante, R. J.; Kowall, N. W.; Beal, M. F. Movement disorder following excitotoxin lesions in primates Neuroreport. 1994, 5 (10) 1259-1261
32. Schwarcz, R.; Whetsell, W. O., Jr.; Mangano, R. M. Quinolinic acid: An endogenous metabolite that produces axon-sparing lesions in rat brain Science 1983, 219 (4582) 316-318
33. Beal, M. F.; Ferrante, R. J.; Swartz, K. J.; Kowall, N. W. Chronic quinolinic acid lesions in rats closely resemble Huntingtons disease J. Neurosci. 1991, 11 (6) 1649-1659
34. Okuda, S.; Nishiyama, N.; Saito, H.; Katsuki, H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 12553-12558
35. Stone, T. W.; Mackay, G. M.; Forrest, C. M.; Catherine, J.; Clark, C. J.; Darlington, L. G. Tryptophan Metabolites and Brain Disorders Clin. Chem. Lab. Med. 2003, 41 (7) 852-859
36. Majláth, Z.; Tajti, J.; Vécsei, L. Kynurenines and other novel therapeutic strategies in the treatment of dementia Ther. Adv. Neurol. Disord. 2013, 6 (6) 386-397
37. Parsons, C. G.; Danysz, W.; Quack, G.; Hartmann, S.; Lorenz, B.; Wollenburg, C.; Baran, L.; Przegalinski, E.; Kostowski, W.; Krzascik, P.; Chizh, B.; Headley, P. M. Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: Electrophysiological, biochemical and behavioral characterization J. Pharmacol. Exp. Ther. 1997, 283, 1264-1275
38. Sapko, M. T.; Guidetti, P.; Yu, P.; Tagle, D. A.; Pellicciari, R.; Schwarcz, R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntingtons disease Exp. Neurol. 2006, 197 (1) 31-40
39. Poeggeler, B.; Rassoulpour, A.; Wu, H. Q.; Guidetti, P.; Roberts, R. C.; Schwarcz, R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity Neuroscience 2007, 148 (1) 188-197
40. Chiarugi, A.; Carpenedo, R.; Moroni, F. Kynurenine disposition in blood and brain of mice: Effects of selective inhibitors of kynurenine hydroxylase and of kynureninase J. Neurochem. 1996, 67 (2) 692-698
41. Speciale, C.; Wu, H. Q.; Cini, M.; Marconi, M.; Varasi, M.; Schwarcz, R. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats Eur. J. Pharmacol. 1996, 315 (3) 263-267
42. Sapko, M. T.; Guidetti, P.; Yu, P.; Tagle, D. A.; Pellicciari, R.; Schwarcz, R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntingtons disease Exp. Neurol. 2006, 197, 31-40
43. Röver, S.; Cesura, A. M.; Huguenin, P.; Kettler, R.; Szente, A. Synthesis and Biochemical Evaluation of N -(4-Phenylthiazol-2-yl)benzenesulfonamides as High-Affinity Inhibitors of Kynurenine 3-Hydroxylase J. Med. Chem. 1997, 40, 4378-4385
44. Moroni, F.; Cozzi, A.; Peruginelli, F.; Carpenedo, R.; Pellegrini-Giampietro, D. E. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia Adv. Exp. Med. Biol. 1999, 467, 199-206
45. Cozzi, A.; Carpenedo, R.; Moroni, F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: Studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia J. Cereb. Blood Flow Metab. 1999, 19 (7) 771-777
46. Samadi, P.; Grégoire, L.; Rassoulpour, A.; Guidetti, P.; Izzo, E.; Schwarcz, R.; Bédard, P. J. Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys Mov. Disord. 2005, 20 (7) 792-802
47. Beconi, M. G.; Yates, D.; Lyons, K.; Matthews, K.; Clifton, S.; Mead, T.; Michael Prime, M.; Winkler, D.; OConnell, C.; Walter, D.; Toledo-Sherman, L. M.; Munoz-Sanjuan, I.; Dominguez, C. Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048 Drug Metab. Dispos. 2012, 40 (12) 2297-2306
48. Courtney, S. M.; Prime, M.; Mitchell, W.; Brown, C. J.; De Aguiar Pena, P. C.; Johnson, P.; Dominguez, C.; Toledo-Sherman, L. M.; Munoz, I. Kynurenine-3-Monooxygenase Inhibitors, Pharmaceutical Compositions and Methods of use Thereof. International Patent WO2013/033085, Mar 7, 2013.
49. Dominguez, C.; Toledo-Sherman, L. M.; Courtney, S. M.; Prime, M.; Mitchell, W.; Brown, C. J.; De Aguiar Pena, P. C.; Johnson, P. Certain Kynurenine-3-Monooxygenase Inhibitors, Pharmaceutical Compositions and Methods of use Thereof. International Patent WO2013/016488, Jan 31, 2013.
50. Miyaura, N.; Suzuki, A. Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds Chem. Rev. 1995, 95 (7) 2457-2483
51. Albaneze-Walker, J.; Bazaral, C.; Leavey, T.; Dormer, P. G.; Murry, J. A. Improved Carbonylation of Heterocyclic Chlorides and Electronically Challenging Aryl Bromides Org. Lett. 2004, 6 (13) 2097-2100
52. van der Westhuyzen, C. W.; Rousseau, A. L.; Parkinson, C. J. Effect of Substituent Structure on Pyrimidine Electrophilic Substitution Tetrahedron 2007, 63 (25) 5394-5405
53. Hayashi, T.; Konishi, M.; Kobori, Y.; Kumada, M.; Higuchi, T. Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II): An effective catalyst for cross-coupling of secondary and primary alkyl Grignard and alkylzinc reagents with organic halides J. Am. Chem. Soc. 1984, 106 (1) 158-163
54. Pearson, R. E.; Martin, J. C. The Mechanism of Benzylic Bromination with N -Bromosuccinimide J. Am. Chem. Soc. 1963, 85 (3) 354-355
55. Bernard, A. M.; Ghiani, M. R.; Piras, P. P.; Rivoldini, A. Dealkylation of Activated Alkyl Aryl Ethers Using Lithium Chloride in Dimethylformamide Synthesis 1989, 4, 287-289
56. Doláková, P.; Masojídková, M.; Holy, A. Efficient Synthesis of Pyrimidinecarbonitriles and Their Derivatives Heterocycles 2007, 71 (5) 1107-1115
57. Finnegan, W. G.; Henry, R. A.; Lofquist, R. An Improved Synthesis of 5-Substituted Tetrazoles J. Am. Chem. Soc. 1958, 80, 3908-3911
58. Charton, J.; Deprez-Poulain, R.; Hennuyer, N.; Tailleux, A.; Staels, B.; Deprez, B. Novel non-carboxylic acid retinoids: 1,2,4-Oxadiazol-5-one derivatives Bioorg. Med. Chem. Lett. 2009, 19 (2) 489-492
59. Santilli, A.; Morris, R. L. Synthesis of 3-Arylsulfonylmethyl-1,2-4-oxadiazole-5-carboxylic Acid Derivatives J. Heterocycl. Chem. 1979, 16 (6) 1197-1200
60. Manley, P. J.; Balitza, A. E.; Bilodeau, M. T.; Coll, K. E.; Hartman, R. C.; McFall, K. W.; Rodman, L. D.; Thomas, K. A. 2,4-Disubstituted pyrimidines: A novel class of KDR kinase inhibitors Bioorg. Med. Chem. Lett. 2003, 13 (10) 1673-1677
61. Winkler, D.; Beconi, M.; Toledo-Sherman, L. M.; Prime, M.; Ebneth, A.; Dominguez, C.; Muñoz-Sanjuan, I. Development of LC/MS/MS, High-Throughput Enzymatic and Cellular Assays for the Characterization of Compounds That Inhibit Kynurenine Monooxygenase (KMO) J. Biol. Screening. 2013, 18 (8) 879-889
62. Krueger, S. K.; Williams, D. E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism Pharmacol. Ther. 2005, 106, 357-387
63. Melo, A.; Ramos, M. J.; Floriano, W. B.; Gomes, J. A. N. F.; Leao, J. F. R.; Magalhães, A. L.; Maigret, B.; Nascimento, M. C.; Reuter, N. Theoretical study of arginine-carboxylate interactions J. Mol. Struct.: THEOCHEM 1999, 463 (1) 81-90
64. Amaral, M.; Levy, C.; Heyes, D. J.; Lafite, P.; Outeiro, T. F.; Giorgini, F.; Leys, D.; Scrutton, N. S. Structural basis of kynurenine 3-monooxygenase inhibition Nature 2013, 496 (7445) 382-385
65. Krajcsi, P.; Jani, M.; Tóth, B.; Erdo, F.; Kis, E.; Beéry, E.; Sziráki, I. Efflux transporters in the blood-brain interfaces-in vitro and in vivo methods and correlations Expert Opin. Drug Metab. Toxicol. 2012, 8 (4) 419-431
66. Jauch, D. A.; Sethy, V. H.; Weick, B. G.; Chase, T. N.; Schwarcz, R. Intravenous administration of L-kynurenine to rhesus monkeys: Effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid Neuropharmacology 1993, 32 (5) 467-472
67. Alexander, K. S.; Wu, H. Q.; Schwarcz, R.; Bruno, J. P. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine Psychopharmacology 2012, 220 (3) 627-637
68. Westerink, B. H. C.; Cremers, T. I. F. H., Eds. Handbook of Microdialyis-Methods, Applications and Clinical Aspects; Academic Press, Elsevier: London, UK. 2007.